"Although revenue came in slightly below our expectations, strong operating performance enabled higher-than-anticipated profitability and cash." (CEO & Director John Heller) "Notable highlights ...
With the recent launches of Novo Nordisk’s Wegovy pill and Eli Lilly’s Foundayo, the obesity market has started to shift toward oral GLP-1 drugs. While Novo leverages its first-mover advantage with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results